恩华药业上半年净利增11%研发投入近4亿元

Core Insights - The company reported a continuous growth in operating performance for the first half of 2025, achieving a revenue of 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% from the previous year [2] - The company specializes in the research and production of central nervous system drugs, with 60 approved new drug formulations and a market share leading in 29 products nationwide [2] Financial Performance - Revenue for the first half of 2025 reached 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [2] - Net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [2] - The net profit after deducting non-recurring gains and losses was 699 million yuan, which is a 10.33% increase from the previous year [2] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of approximately 395 million yuan, representing a 23.97% increase year-on-year [2] - There are currently 17 innovative drug projects under development, including 1 project in Phase III clinical trials and 2 projects in Phase II clinical trials [3] - The company has signed a Pre-A round preferred stock purchase agreement with San Sheng Pharmaceutical, gaining priority negotiation rights for certain in-development drugs [3] Collaborations and Partnerships - The company has entered into a commercial cooperation agreement with Chengdu Yuandong Biopharmaceutical Co., Ltd. for the market development of its Oxycodone tablets [3] - The NHL35700 drug, introduced from Denmark, has completed Phase II clinical trials and is set to enter Phase III trials [3] - The Protollin project, developed in collaboration with Harvard Medical School and Tianjing Biotech, has successfully completed Phase I clinical trials in the U.S. and is moving to Phase II trials [3]